# Open-label Study of IMGN779 in Adult Patients With Relapsed/Refractory CD33-positive Acute Myeloid Leukemia

> **NCT02674763** · PHASE1 · COMPLETED · sponsor: **ImmunoGen, Inc.** · enrollment: 62 (actual)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **DRUG:** IMGN779

## Key facts

- **NCT ID:** NCT02674763
- **Lead sponsor:** ImmunoGen, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-03
- **Primary completion:** 2019-06
- **Final completion:** 2019-07
- **Target enrollment:** 62 (ACTUAL)
- **Last updated:** 2019-09-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02674763

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02674763, "Open-label Study of IMGN779 in Adult Patients With Relapsed/Refractory CD33-positive Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02674763. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*